Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2Thoracic 1Sarcoma 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Carcinoma, Renal Cell 26Prostatic Neoplasms 5Osteosarcoma 5Neuroendocrine Tumors 5Neoplasms 5Kidney Neoplasms 5Colorectal Neoplasms 5Carcinoma, Hepatocellular 5Neoplasm Metastasis 4Urinary Bladder Neoplasms 3Urethral Neoplasms 3Sarcoma, Ewing 3Sarcoma 3Clear-cell metastatic renal cell carcinoma 3Carcinoma, Transitional Cell 3Carcinoma, Non-Small-Cell Lung 3Carcinoma, Medullary 3Urogenital Neoplasms 2Ureteral Neoplasms 2Small Cell Lung Carcinoma 2Penile Neoplasms 2Melanoma 2Lung Neoplasms 2Central Nervous System Neoplasms 2Carcinoma 2Adrenocortical Carcinoma 2von Hippel-Lindau Disease 1Wilms Tumor 1Urachal adenocarcinoma 1Triple Negative Breast Neoplasms 1

Interventions

pembrolizumab 57Nivolumab 50Ipilimumab 31Specimen Handling 23Magnetic Resonance Spectroscopy 19Cyclophosphamide 14Biopsy 11fludarabine 10binimetinib 10Opdualag 10trametinib 9relatlimab 9Radiosurgery 9CTLA-4 Antigen 9dabrafenib 8lifileucel 7fludarabine phosphate 7aldesleukin 7encorafenib 6Interleukin-2 6cemiplimab 5atezolizumab 5Paclitaxel 5Blood Specimen Collection 5X-Rays 4Taxes 4Pemetrexed 4Gemcitabine 4Cisplatin 4Carboplatin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Melanoma × cabozantinib × 90 days × Clear all
NCT05136196 2026-06-05

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

National Cancer Institute (NCI)

Phase 2 Recruiting
150 enrolled
DermatologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Melanoma, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT04514484 2026-05-28

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

National Cancer Institute (NCI)

Phase 1 Active not recruiting
8 enrolled 32 charts
BreastDermatologicGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Kaposi, HIV Infections, Carcinoma, Medullary, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡